From the pharmacological point of view, given the progressive development of specific MIF and DDT inhibitors in the clinical setting [8], it will be important to ascertain the safety of these agents in patients with DLE and also to consider the inclusion of ad hoc safety studies to rule out possible iatrogenic induction of DLE lesions. The gene discussed is MIF; the disease is discoid lupus erythematosus.